Literature DB >> 9229100

Maxillary myxoma treated with wide resection and immediate reconstruction: a case report.

C T Chen1, Y R Chen, J P Lai, T C Tung.   

Abstract

Myxoma of the jaw is a rare, benign bone tumor of odontogenic origin. Given the locally aggressive nature of the myxoma and the high rate of recurrence, there is a tendency to choose radical resection of the jaw segment containing the tumor mass as the treatment modality. As they appear to attain a considerable size prior to diagnosis because of their insidious growth characteristics, particularly in the maxilla, treatment requiring a hemimaxillectomy often results in a significant functional and aesthetic disability. This is particularly distressing as this condition usually affects the young. We present the case of a 16-year-old female who suffered a large maxillary myxoma with swelling of the left cheek for 2 years. Wide resection of the tumor tissue including the maxillary medial and lateral buttresses and part of the hard palate with preservation of maxillary alveolar bone and teeth was undertaken, and the maxillary buttresses were reconstructed with autogenous rib grafts. At the 3.5-year follow-up there was no local recurrence and no tooth loss. Both the functional result and aesthetic contour proved satisfactory. Wide resection with preservation of vital structures and simultaneous autogenous bone graft reconstruction is our preferred method. A long-term follow-up is needed.

Entities:  

Mesh:

Year:  1997        PMID: 9229100     DOI: 10.1097/00000637-199707000-00016

Source DB:  PubMed          Journal:  Ann Plast Surg        ISSN: 0148-7043            Impact factor:   1.539


  2 in total

Review 1.  Fibromyxoma of the Jaw: Case Report and Review of the Literature.

Authors:  Thabet Alhousami; Amarpreet Sabharwal; Shivane Gupta; Alfredo Aguirre; Etern Park; Jill M Kramer
Journal:  Head Neck Pathol       Date:  2017-05-16

2.  Odontogenic myxoma of the maxilla: surgical management and case report.

Authors:  C Murphy; R Hayes; M McDermott; G J Kearns
Journal:  Ir J Med Sci       Date:  2016-03-14       Impact factor: 1.568

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.